Biocryst Pharmaceuticals Inc Dossier
Financial Snapshot
Revenue, profitability, returns, debt, and capital allocation
Revenue $940.6M+108.7% YoYTTM through 30 Jun 2026
Net Income -$384.7MTTM through 30 Jun 2026
Free Cash Flow $373.4MTTM through 30 Jun 2026
Margins
| Current | |
|---|---|
| EBITDA Margin | -33.1% |
| Operating Margin | 39.0% |
| Net Margin | -40.9% |
Returns
-221.5%ROE
51.3%ROA
Balance Sheet Health
Debt / Equity-3.91x
Current Ratio2.32x
Net Debt$128.2M
Cash & Equivalents$155M
Quality Metrics
Altman Z-Score-3.64
Piotroski F-Score5 / 9
FCF Margin39.7%
Earnings-Beat Rate100.0%
Multi-Year Trend
RevenueFY2025: $874.8M
Diluted EPS-$1.40TTMFY2025: $1.21
Dividend
No dividend
Capital Allocation
R&D Spend$197.8M
Capex Intensity0.3%
Segment Performance
| Segment | Revenue | YoY | Outlook |
|---|---|---|---|
| Discovery, Development and Commercialization of Novel Therapeutics | $874.8M | +94.1% | View detailsMaintained full year 2026 global net ORLADEYO revenue guidance between $625 million and $645 million, and total revenue guidance between $635 million and $660 million. |
Filing Detail Members
This section is available to registered members. Create a free account or sign in to unlock the full breakdown.